Loading…
Veradermics, Incorporated is projected to rise to $131.08 by 2027, a +25% move from its current price of $104.63. MANE is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $100.04 | $104.72 | $109.61 | +0.08% |
| Aug 2 | $98.25 | $104.80 | $111.79 | +0.16% |
| Aug 3 | $96.91 | $104.89 | $113.51 | +0.24% |
| Aug 4 | $95.81 | $104.97 | $115.01 | +0.33% |
| Aug 5 | $94.86 | $105.06 | $116.35 | +0.41% |
| Aug 6 | $94.02 | $105.14 | $117.58 | +0.49% |
| Aug 7 | $93.26 | $105.23 | $118.73 | +0.57% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $93.26 | $105.23 | $118.73 | +0.57% |
| Week 2 | $89.21 | $105.83 | $125.54 | +1.14% |
| Week 3 | $86.34 | $106.43 | $131.20 | +1.72% |
| Week 4 | $84.07 | $107.04 | $136.28 | +2.30% |
| Week 5 | $82.17 | $107.65 | $141.03 | +2.89% |
| Week 6 | $80.54 | $108.27 | $145.53 | +3.47% |
| Week 7 | $79.10 | $108.88 | $149.88 | +4.07% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Veradermics, Incorporated is a healthcare company that operates as a clinical-stage biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. Its products include VDPHL01, an oral, non-hormonal treatment for men and women with Pattern Hair Loss for chronic hair loss therapy; VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum.
Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.
Veradermics trades under the symbol MANE and currently has a price of $104.63 per share, with a market capitalization of $4.37B. It ranks 1377 by market cap among public companies. The stock carries a high level of volatility, with an annualized volatility of 90%.
The current chart shows neutral near-term momentum, with a 30-day trading range and technical levels to monitor. Forecasts imply a bullish longer-term outlook, with average prices rising from the near-term level and substantial upside potential reflected in later years.
A major floor 45.8% below — a decisive break under it would weaken the trend.
The nearest floor, 12.2% below — buyers have tended to step in here.
The nearest ceiling, 24.0% above — a clean break opens room to run.
A major ceiling 40.1% above — clearing it would confirm fresh momentum.
Key MANE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MANE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $108.97 | Sell | $108.32 | Sell |
| MA 10 | $109.74 | Sell | $110.00 | Sell |
| MA 20 | $113.93 | Sell | $111.14 | Sell |
| MA 50 | $107.47 | Sell | $106.23 | Sell |
| MA 100 | $92.13 | Buy | $93.44 | Buy |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.90 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -104.31 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -1.43 | Sell |
| ROC (12) | -5.03 | Sell |
| Bollinger %B (20,2) | 0.16 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.16 | Buy |
| Awesome (5,34) | -2.41 | Sell |
| Ultimate (7,14,28) | 41.32 | Neutral |
| Momentum (10) | -1.20 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 108.06 | Sell |
| ADX (14) | 11.20 | Neutral |
| ATR (14) | 4.57 | Info |
The 30-day picture is NEUTRAL. The RSI(14) is 40, indicating modest momentum. The stock trades near the 50-day simple moving average at $107.47, with the current price at $104.63. Support sits at $91.87 and resistance at $129.74, framing a 30-day range from $77.44 to $141.36.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $37.03 | $104.63 | $156.82 | 0% | Neutral | |
| $90.19 | $131.08 | $206.57 | +25% | Bullish | |
| $89.81 | $142.01 | $241.86 | +36% | Bullish | |
| $105.14 | $178.93 | $323.05 | +71% | Bullish | |
| $131.42 | $239.39 | $453.33 | +129% | Bullish | |
| $150.64 | $292.75 | $577.42 | +180% | Bullish | |
| $180.04 | $372.67 | $761.87 | +256% | Bullish | |
| $177.06 | $389.92 | $822.97 | +273% | Bullish | |
| $168.53 | $374.50 | $813.65 | +258% | Bullish | |
| $203.98 | $453.30 | $1,011.31 | +333% | Bullish | |
| $358.45 | $796.56 | $1,832.10 | +661% | Bullish | |
| $961.36 | $2,136.36 | $4,913.62 | +19.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $37.03 | $104.63 | $123.14 | +0.00% |
| August 2026 | $91.73 | $111.19 | $140.42 | +6.27% |
| September 2026 | $90.96 | $112.68 | $146.88 | +1.34% |
| October 2026 | $86.35 | $108.88 | $145.45 | -3.37% |
| November 2026 | $86.02 | $110.07 | $149.95 | +1.09% |
| December 2026 | $87.21 | $113.11 | $156.82 | +2.76% |
Click any year to see its month-by-month MANE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Veradermics, Incorporated's 2026 outlook centres on $104.63, within a $37.03 to $156.82 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, MANE could reach as high as $206.57, with a base case around $131.08 and support toward $90.19 — roughly +25% from $104.63. Buyers look set to stay in control over this stretch.
Expect MANE to range from $89.81 to $241.86 through 2028. The $142.01 average target implies a +36% move from current prices. That is up +8% on the projected 2027 average. Momentum favours further upside here.
The MANE price prediction for 2029 points to an average of $178.93 (low $105.14, high $323.05) — a potential gain of +71% on today's $104.63. Buyers look set to stay in control over this stretch.
In 2030, MANE is projected to trade between $131.42 and $453.33, averaging $239.39 — a potential gain of +129% from today's $104.63. That is up +34% on the projected 2029 average. Momentum favours further upside here.
Veradermics, Incorporated's 2031 outlook centres on $292.75, within a $150.64 to $577.42 range. That is up +22% on the projected 2030 average. That marks a +180% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, MANE could reach as high as $761.87, with a base case around $372.67 and support toward $180.04 — roughly +256% from $104.63. Momentum favours further upside here.
Expect MANE to range from $177.06 to $822.97 through 2033. The $389.92 average target implies a +273% move from current prices. That is up +5% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The MANE price prediction for 2034 points to an average of $374.50 (low $168.53, high $813.65) — a potential gain of +258% on today's $104.63. Momentum favours further upside here.
In 2035, MANE is projected to trade between $203.98 and $1,011.31, averaging $453.30 — a potential gain of +333% from today's $104.63. That is up +21% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Veradermics, Incorporated's 2040 outlook centres on $796.56, within a $358.45 to $1,832.10 range. That is up +76% on the projected 2035 average. That marks a +661% change versus current levels. Momentum favours further upside here.
By 2050, MANE could reach as high as $4,913.62, with a base case around $2,136.36 and support toward $961.36 — roughly +19.4x from $104.63. Buyers look set to stay in control over this stretch.
Investing $1,000 in MANE today (≈ 9.557488 MANE) could be worth
$20,418.2
+$19,418.2 (+1942%) by 2050 · US Dollar
Based on the average projected MANE price of $2,136.36 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MANEwould be worth at today's price.
$1,000 invested in MANE on Feb 4, 2026 (≈ 26.490066 MANE) would be worth
$2,771.66
+$1,771.66 (+177.2%) today · 2.77× · US Dollar
Based on a MANE entry price of $37.75 vs. today's $104.63.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $115.86 | $903.07 | -9.7% |
| 1 month ago | $122.94 | $851.07 | -14.9% |
| 3 months ago | $101 | $1,035.94 | +3.6% |
| All time ago | $37.75 | $2,771.66 | +177.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MANE forecast.
Our base-case forecast reaches $210.00 around 2030.
Implied market cap at $210.00: $8.77B
The multi-year forecast shows a bullish trajectory from 2027 onward. The 2026 average price is $104.63 with a 0% ROI. By 2027 the average rises to $131.08 (ROI 25.3%), 2028 to $142.01 (ROI 35.7%), and 2029 to $178.93 (ROI 71%).
By 2030 the average is $239.39 (ROI 128.8%), by 2031 $292.75 (ROI 179.8%), by 2032 $372.67 (ROI 256.2%), by 2033 $389.92 (ROI 272.7%), by 2034 $374.50 (ROI 257.9%), and by 2035 $453.30 (ROI 333.2%). The path continues to 2040 with an average of $796.56 (ROI 661.3%), and to 2050 with an average of $2,136.36 (ROI 1,941.8%). The max forecast values rise to $453.33 (2030), $1,832.10 (2040), and $4,913.62 (2050).
The sentiment is bullish from 2027 onward, reflecting strong upside potential, though these figures are estimates and not guarantees.
Tap a question to reveal the answer.
Average price $239.39, min $131.42, max $453.33, ROI 128.8%, sentiment bullish.
Forecast shows bullish sentiment from 2027 onward, with average price rising to $239.39 by 2030 and to $2,136.36 by 2050; ROI climbs to 128.8% by 2030 and 1,941.8% by 2050. These are estimates, not guarantees.
Yes — the 2035 max is $1,011.31, with earlier years hitting up to $453.33 in 2030 and $1,832.10 in 2040; the 2050 max is $4,913.62.
Current price $104.63; market cap $4.37B.
30-day range: low $77.44, high $141.36.
Veradermics, Incorporated Community Discussion
0Share your Veradermics, Incorporated price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.